Satraplatin is under clinical development by Pharmaand and currently in Phase II for Primary CNS Lymphoma. According to GlobalData, Phase II drugs for Primary CNS Lymphoma have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Satraplatin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Satraplatin overview

Satraplatin is under development for the treatment of primary CNS lymphoma and T-cell lymphoma. The drug candidate is a fourth-generation orally bioavailable precision platinum compound and acts by targeting DNA. It is being developed based on Artificial Intelligence (AI) platform.

Pharmaand overview

pharmaand (Pharma), formerly Zr Pharma, is a manufacturer and distributor of pharmaceutical products. The company acquires and markets the authorization and worldwide rights of different products in various therapeutic areas such as urology, cardiovascular diseases and diseases of the central nervous system, gastroenterology, pneumology, and haematology, for patients and doctors worldwide. Its product offerings include coated tablets, divisible tablets, injections, gastro-resistant tablets, syrups, and capsules. The company’s service offerings include product development, distribution services, and lifecycle management. It markets its products through its brands such as Anafranil, Androskat, Asacol, Dridase, Emselex, Euphyllin, Farydak, Levact, and Pegasys. Pharma is headquartered in Vienna, Austria.

For a complete picture of Satraplatin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.